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ABSTRACT
The use of cytolytic effector cells as therapy for malignant disease has been a central focus of basic and clinical
research for nearly 2 decades. Since the original descriptions of in vitro lymphocyte-mediated cytotoxicity
against human tumor cells, there have been numerous attempts to exploit such observations for therapeutic
use, with decidedly mixed results. Most studies have focused on the role of either natural killer cells or
cytotoxic CD8 T cells as the primary mediators of antitumor cytotoxicity, and until recently little attention
has been paid to the role of  T cells in this capacity. This is partially due to a lack of understanding of the
mechanisms of T-cell immune responses to tumors, as well as the practical problem of obtaining a sufficient
number of  T cells for clinical-scale administration. In this article, we discuss the biological and clinical
rationale for developing  T cell–based immunotherapies for the treatment of a variety of malignant
conditions. It is our view that infusing supraphysiological numbers of tumor-reactive  T cells—either in the
autologous or allogeneic setting—might be used to restore or augment innate immune responses against
malignancies. Accordingly, we will also discuss how we and others are working to overcome some of the
practical limitations that have so far limited the direct clinical delivery of highly purified human  T cells for
the treatment of both hematologic and solid tumors.
© 2005 American Society for Blood and Marrow Transplantation
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The transfer of cytolytic effector cells into tumor-
earing hosts with the intent to eradicate disease has
een the focus of a great deal of basic and clinical
esearch for nearly 2 decades [1-13]. Since the original
escriptions of lymphocyte-mediated cytotoxicity
gainst human tumor cells in vitro, there have been
umerous attempts to exploit such observations for
herapeutic use in humans, with decidedly mixed re-
ults [5,14-16]. Clinical applications of adoptive cellu-
ar immunotherapy have included the treatment of
atients with various malignancies (such as melanoma)
y using interleukin (IL)–2–stimulated lymphokine-
ctivated killer cells derived from autologous periph-
ral blood. Similarly, tumor-inﬁltrating lymphocytes,
rst isolated from primary tumors and subsequently
ultured and expanded ex vivo, have also been admin-
stered clinically. Although historically a great deal of s
B&MTmphasis has been placed on the role of either natural
iller (NK) cells or cytotoxic CD8  T cells as the
rimary mediators of antitumor cytotoxicity [17-24],
ntil now little attention has been paid to the role of
uman  T cells in this capacity.
 T CELLS FORM PART OF THE INNATE IMMUNE
EFENSE AND ARE POTENT ANTITUMOR EFFECTORS
Whereas most mature T cells express the 
-cell receptor (TCR) heterodimer, a small propor-
ion express an alternative  TCR heterodimer [25-
8]. Unlike  T cells, which recognize speciﬁc pro-
essed peptide antigens presented on major
istocompatibility complex (MHC) molecules by an-
igen-presenting cells,  T cells seem to directly
ecognize and respond to a variety of MHC-like
tress-induced self-antigens expressed by malignant
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1ells [29-33]. Thus,  T cells can recognize malig-
ant cells through less speciﬁc mechanisms that re-
uire no prior antigen exposure or priming, a function
hat is shared by other innate immune cells such as
acrophages and NK cells [25]. Although  T cells
omprise10% of total peripheral blood T cells, they
re present in substantially greater numbers within
pithelial tissues such as skin, intestine, and lung [34-
7], contrasting with  T cells, most of which either
irculate in the peripheral blood or are resident in
ymphoid organs.
The process by which  T cells recognize
tressed or malignant cells is not completely under-
tood. Although the TCR is involved in antigen rec-
gnition [38], the mechanism by which antigens are
ecognized by  T cells is fundamentally different
rom that for both  T cells and NK cells [25,39].
lthough a detailed discussion on the biology of 
-cell recognition and the shaping of the  T-cell
epertoire is beyond the scope of this article (several
xcellent reviews on this subject are available [39-42]),
t is important to note that both genetic and extrinsic
actors, such as environmental antigens, likely play a
ey role in shaping the  T-cell repertoire.
Several lines of evidence point to a role for T cells
n tumor immunosurveillance. It has recently been
hown that mice lacking T cells are highly susceptible
omultiple regimens of cutaneous carcinogenesis [29]. In
linical studies,  T cells have been shown to inﬁltrate
variety of tumors, including lung cancer [43,44], renal
ell carcinoma [45], seminoma [46], and breast cancer
47]. The most common circulating  T cells, ie, those
xpressing the V9/V2 TCR heterodimer (sometimes
esignated V2V2, because V9 forms part of the V2
ene family) [48], recognize several known tumor-
ssociated ligands and cell lines. These include HSP-60
49,50], Daudi Burkitt lymphoma [51,52], and glial cells
52]. V9/V2  T cells recognize and lyse glioblastoma
53], neuroblastoma [54], multiple myeloma [55], and lung
ancer [56]. CD30-restricted V9V2 T cells have been
solated from patients withHodgkin disease [57], and V9/
2 T cells recognize cells with increased mevalonate me-
abolites, which are overexpressed in hematologic malig-
ancies and mammary carcinoma cells [58].
V1 T cells are less frequent, comprising up to
0% of all  T cells. They seem to recognize a
ifferent set of ligands and tumors, although there is
ome overlap with V2 cells. A high proportion of
1  T cells appear in epithelial tumors from
ung, breast, kidney, ovary, prostate, and colon that
xpress the stress-induced antigens MICA and MICB
59], a nonclassic stress-related MHC antigen recog-
ized by V1 cells [60]. Primary leukemias are also
re killed by  T cells. Duval et al. [61] showed that
 T cells isolated from patients with leukemia ex-
anded in IL-2–containing cultures to a greater de-
ree than  T cells isolated from healthy controls. (
621 and V2 T cells both expanded, and the V1
lones lysed the acute lymphoblastic leukemia (ALL)
ell line NALM-6. Lamb et al. [62] later showed that
1 T cells proliferated when cultured with primary
cute leukemia cells and became cytotoxic to the pri-
ary leukemia but did not lyse normal lymphocytes.
n addition, V1  T cells seem to recognize
pstein-Barr virus–transformed B cells [63], primary
lasts obtained from patients with acute myeloid leu-
emia acute myeloid leukemia [64] and B-cell ALL
61], and lung cancer–derived cell lines [65]. How-
ver, the means by which  T cells recognize these
argets are not yet understood.
EVERAL PROPERTIES OF HUMAN  T CELLS MAKE
HEM PARTICULARLY SUITABLE FOR INTENSIVE
TUDY IN THE SETTING OF HEMATOPOIETIC STEM
ELL TRANSPLANTATION
A number of in vitro and in vivo studies suggest
hat  T cells might be ideally suited for study spe-
iﬁcally in the context of hematopoietic stem cell
ransplantation (HSCT). First,  T cells can mediate
nnate antitumor activity. Second, evidence suggests
hat  T cells might be capable of facilitating alloge-
eic engraftment. Moreover, it seems that  T cells
ikely to do not initiate graft-versus-host disease
GVHD). Despite these intriguing ﬁndings, however,
ew studies speciﬁcally address the role of  T cells in
he setting of clinical HSCT.
ssociation between Allogeneic Graft  T-Cell
ontent and Disease-Free Survival
The ﬁrst indication that  T cells might protect
gainst disease relapse in bone marrow transplantation
BMT) patients was reported by Lamb et al. [66] in a
tudy of patients undergoing allogeneic HSCT for
LL or AML. In this report, it was noted that several
atients who received bone marrow grafts depleted of
 T cells subsequently developed spontaneous in-
reases in  T-cell numbers during the ﬁrst year after
SCT. These patients were found to have a signiﬁ-
ant improvement in disease-free survival (DFS) when
ompared with similar-risk patients. It is interesting to
ote that the absolute increase in  T cells persisted
n surviving patients for up to several years after trans-
lantation. In a follow-up study, it was determined
hat a post-BMT absolute increase in  T cells was
igniﬁcantly associated with  T-cell depletion, be-
ause patients who received grafts that were T-cell
epleted with OKT3, a pan T-cell monoclonal anti-
ody, rarely showed an increase in  T cells after
MT (P  .05) [67]. Finally, Godder et al. [68] re-
ently showed that the improved DFS of patients with
ncreased  T cells is sustained over several years
Figure 1).
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Immunotherapeutic Potential of  T Cells
BTo date, no studies have been performed in which
 T cells have been speciﬁcally introduced as a part of
n allogeneic hematopoietic stem cell product. Out-
omes from patients who received  T-cell–depleted
llogeneic grafts (leaving  T cells in the infused prod-
ct) have been compared with outcomes from patients
ho received pan–T-cell–depleted grafts, thus providing
nformation on the impact of an allogeneic  T-cell–
eplete graft on immune recovery, survival, and inci-
ence/severity of GVHD. In a single-center study of 535
atients who received grafts T cell–depleted with the
nti- monoclonal antibody T10B9-1A.31 or the anti-
D3 (pan) T-cell antibody OKT3, Keever-Taylor et al.
69] showed no difference in DFS for either T-cell de-
letion method. In a separate single-center study of 201
atients who underwent haploidentical BMT, Mehta
t al. [70] did show improved DFS in patients who
eceived T10B9-1A.31 T-cell depletion. It is important
o note, however, that neither of these studies speciﬁcally
ddressed outcomes related to  T-cell therapy. More-
igure 1. Comparison of disease-free survival in ALL (A) and AML
B) patients with increased  T cells after BMT and patients with
ormal recovery of  T cells. Note the signiﬁcantly improved
isease-free survival and the lower incidence of relapse in the
roups with increased  T cells.ver, the speciﬁc role of  T cells on disease relapse, b
B&MTith the possible exception of the studies on patients
ith measured post-BMT increases in  T cells, is
ifﬁcult to interpret because the  T-cell dose was not
ecorded and therefore was not included in the statistical
nalysis. Deﬁned  T-cell dose-escalation studies in
umans are essential to determine whether  T cells
ill protect against relapse.
t Is Unlikely That  T Cells Initiate GVHD
Both murine and human studies suggest that  T
ells are not primary initiators of GVHD and may in
act modulate the GVHD activity of  T cells.
robyski et al. [71] showed that large doses of IL-2–
xpanded  T cells could be infused into lethally
rradiated MHC-disparate mice (C57BL/6 [H-2b] 
10.BR [H-2k] and C57BL/6 [H-2b]  B6D2F1
H-2b/d]) without causing GVHD. Ellison et al. [72]
oted that  T cells were activated in the GVHD
eaction but found no evidence that GVHD was ini-
iated by  T cells. This work is agreement with later
tudies by Drobyski et al. [73], who showed that al-
hough activated  and naive  T cells exacerbated
VHD when infused together, delaying the infusion
f  T cells by 2 weeks resulted in improved survival.
In human studies, Schilbach et al. [54] and Lamb
t al. [62] found  T cells not to be substantially acti-
ated in the in vitro allogeneic mixed lymphocyte cul-
ure. Several post-BMT studies have shown transient
ncreases in  T cells [74-76] but have not associated
his ﬁnding with GVHD, although Tsuji et al. [77]
ound that  T cells could be recruited into lesions and
ctivated by CD4  T cells. Several studies that com-
ared outcomes of patients who received  T cell–
epleted grafts with those of patients who received pan
cell–depleted grafts all showed a lower incidence of
VHD in the  T cell–depleted group, thus suggest-
ng that infusion of  T cells in the graft does not
ubject the patient to an increased risk of GVHD
69,70,78]. Whether  T cells are truly less likely to
ontribute to the development of GVHD remains un-
ested. However, from the previous reasoning, it is both
ogical and rational to propose that in future studies, 
cells might indeed be introduced in the setting of
llogeneic HSCT—speciﬁcally to provide an innate an-
itumor effect—yet represent only a minimal risk of
ausing GVHD.
nimal Studies and Indirect Evidence from
uman Allogeneic Transplantation Studies
uggest That  T Cells Can Also
acilitate Alloengraftment
Blazar et al. [79], in a murine allogeneic transplan-
ation model, found that that donor  T cells facilitate
he engraftment of T cell–depleted donor bone marrow.
hen T cell–depleted marrow from the severe com-ined immunodeﬁcient mouse strain C.B17-scid/scid
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1H2d, T10d) was supplemented with up to 3 106  T
ells, engraftment into sublethally irradiated B6 mice
as signiﬁcantly improved over B6 mice receiving TCD
arrow alone. Drobyski andMajewski [80] noted similar
ndings when C56BL/6(H2b) donor marrow was sup-
lemented with  T cells prior to transplantation into
10.BR (H-2k) recipients. In addition, the T cell dose
ecessary to facilitate engraftment did not result in lethal
VHD [71]. Neipp et al. [81] showed similar ﬁndings in
rat model in which lethally irradiated (Wistar Furth
F-RT1A) rats were reconstituted with 1  108 
cell–depleted bone marrow. All animals engrafted
ith a mean of 92% 	 4% donor cells and no clinical
vidence of GVHD. Studies comparing patients who
eceived  T cell–depleted grafts with those receiving
an T cell–depleted grafts also show a positive associa-
ion between the number of clonable  T cells in the
raft and less time to engraftment [82,83].
BSTACLES REMAIN TO CLINICAL APPLICATION OF
 T-CELL THERAPY, BUT THESE ARE
EING OVERCOME
Given the previously described information, it
tands to reason that it might be possible to develop
linical strategies whereby human  T cells are spe-
iﬁcally introduced or incorporated as part of an allo-
eneic HSCT product when transplantation is per-
ormed for the treatment of various malignancies.
evertheless, the difﬁculty of isolating suitable num-
ers of human  T cells given their relative infre-
uency in peripheral blood has remained a major
bstacle to the development of clinical models to ex-
loit the innate antitumor activity of human 
cells. In addition, human  T cells cannot readily
e expanded. We and others have come to recognize
hat in vitro, standard culture methods used to expand
uman T cells are unsuitable for the expansion of 
cells because the strong T-cell mitogens often used
an directly induce apoptosis in  T cells; they are
xtremely sensitive to activation-induced cell death
84-87].
The development of protocols for T cell–based
doptive cellular immunotherapy has been seriously
ampered by their sensitivity to activation-induced
ell death, which has prevented the clinical-scale
xpansion of  T cells. In a series of recent publica-
ions, however, our laboratory has identiﬁed and
haracterized a CD2-mediated, IL-12–dependent sig-
aling pathway that inhibits apoptosis in mitogen-
timulated human  T cells [87,88]. Our working
odel proposes that CD2-mediated, IL-12–depen-
ent signals lead to the preferential expression of the
L-15 receptor  (IL-15R) chain over the IL-2R
hain in  T cells. By our convention, these  T
ells are referred to as “protected”  T cells. In c
64ontrast,  T cells that receive no CD2-mediated,
L-12–dependent signals (referred to as “unpro-
ected”  T cells) persist in their expression of the
L-2R chain and, thus, remain exquisitely sensitive
o apoptosis induced by IL-2 [85]. Responsiveness to
L-2 or IL-15 is determined by the respective expres-
ion of either the IL-2R or the IL-15R chain in
ssociation with the  chain and the common  chains.
ur model proposes that a coordinated downregula-
ion of the IL-2R chain and a corresponding upregu-
ation of the IL-15R chain occur as a consequence of
D2-mediated, IL-12–dependent signaling. Given
he contrary effects of IL-2 and IL-15 on mitogen-
timulated  T cells, we propose that CD2-mediated
ignals, through the effects of IL-12, determine the
ate of mitogen-stimulated  T cells by altering their
esponsiveness to IL-2 and IL-15 [88]. Indeed,  T
ells that are induced to express the IL-15R chain
message and protein), which in turn can respond to
L-15, subsequently express substantially higher levels
f message for bcl-2: this is likely important in the
cquisition of an apoptosis-resistant phenotype. Al-
hough the biologic and antitumor characteristics of
uman  T cells expanded in this manner have not
een completely characterized, initial studies are cur-
ently being performed to determine the in vivo efﬁ-
acy and safety in a human/mouse xenograft model.
These ﬁndings are important for both practical
nd clinical reasons. First, by exploiting this signaling
athway, development of methods that permit the
arge-scale ex vivo expansion of viable, apoptosis-
esistant human  T cells has been made possible.
oreover, expanded  T cells—whether derived
rom normal healthy donors or from cancer patients—
etain signiﬁcant innate, MHC-unrestricted cytotox-
city against a wide variety of human-derived tumor
ell lines, including myeloma, leukemia, melanoma,
on–small-cell lung carcinoma, hepatocellular carci-
oma, and ovarian and breast carcinoma cell lines
55,87,89].
Future studies must be designed to determine
hether infusion of supraphysiologic numbers of T
ells will restore or augment innate immune responses
gainst selected malignant diseases and thus moderate
isease progression or the likelihood of relapse after
tandard initial therapy. Allogeneic HSCT, for rea-
ons discussed previously, may be the optimal setting
o study the effects of  T-cell therapy. Donor-
erived  T cells would be incorporated into the
ransplantation procedure as a donor lymphocyte in-
usion (DLI). DLI is sometimes used as nonspeciﬁc
ellular therapy for disease relapse or as prophylaxis
gainst relapse after allogeneic HSCT [90-96]. Be-
ause DLI is usually performed by delivery of unfrac-
ionated donor T-cell preparations consisting primar-
ly of  T cells, severe GVHD is a common
omplication. Given the potentially lower risk for ini-
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Immunotherapeutic Potential of  T Cells
Biation of GVHD by  T cells, it may be possible to
eliver donor-derived  T-cell DLI early after non-
yeloablative allogeneic HSCT with a minimal risk of
VHD.
Alternatively, it has been shown that autologous
umor-reactive  T cells can be expanded from pa-
ients and that these expanded cells retain signiﬁcant
nnate antitumor cytotoxicity in vitro. Therefore, it is
ossible that autologous tumor-reactive  T cells can
rst be obtained from a patient, expanded ex vivo,
ossibly cryopreserved, and then administered in su-
raphysiologic numbers at a subsequent point—likely
n conjunction with other more standard therapies.
uch a strategy would rely in large measure on the
nnate ability of  T cells to recognize and eradicate
esidual malignant disease. However, to rationally de-
elop this model, several important questions must
rst be addressed, including determining the optimal
oint during a patient’s clinical course to collect, ex-
and, and cryopreserve autologous  T cells. Simi-
arly, it would be necessary to determine at what point
einfusion of expanded autologous  T cells might be
erformed to best exploit their innate antitumor ac-
ivity.
Finally, recent studies have shown that pharma-
ologic therapy with aminobisphosphonate drugs
an be used to activate and expand  T cells in
ivo, thereby inducing a  T cell–mediated anti-
umor effect [55,97]. Dieli et al. [98] recently
howed that zoledronic acid administration results
n activation and proliferation of peripheral blood
 T cells in several patients with solid tumors. In
ddition, Kunzmann et al. [55] documented a mea-
urable  T cell–mediated antiplasma cell effect in
one marrow cultures derived from multiple-my-
loma patients. This effect is lost when  T cells
re removed from culture. Wilhelm et al. [97] later
howed that IL-2 in combination with pamidronate
as effective in inducing a measurable reduction of
ultiple myeloma and non-Hodgkin lymphoma in 3
f 5 patients in whom  T cells numbers were
ncreased. In addition,  T-cell cytokine (interferon ,
umor necrosis factor , and IL-6) production was in-
reased after a single infusion of pamidronate. It is there-
ore logical that aminobisphosphonate and  T-cell
herapy may be an effective immunotherapeutic ap-
roach to sensitive tumors such as myeloma, lymphoma,
nd breast cancer.
ONCLUSIONS AND FUTURE DIRECTIONS
Learning to exploit the innate antitumor properties
f human  T cells—particularly as a complement to
he more classic adaptive immune responses—may allow
s to improve our current abilities to treat a variety of
alignant hematologic diseases for which allogeneic
B&MTSCT is commonly used. However, given the biology
f  T cells—particularly their innate ability to rec-
gnize and kill malignancies of epithelial origin—the
xciting prospect of extending allogeneic HSCT to
he treatment of diseases other than those routinely
pproached with allogeneic HSCT must now also be
onsidered.
Barriers to the use of  T cells for such therapy—
peciﬁcally, their relative scarcity and tendency to un-
ergo activation-induced cell death—are now being
vercome. Recent studies have shown that large num-
ers of  T cells that retain signiﬁcant antitumor
ctivity can be produced with methods that are easily
daptable to current cell-processing regulatory re-
uirements. Techniques are currently being devel-
ped for cyclic guanosine monophosphate–compat-
ble clinical-scale ex vivo expansion of  T cells. The
rst clinical trials are expected within the next 6 to
2 months.
For these reasons, we envision that in the setting
f nonmyeloablative allogeneic HSCT, it will eventu-
lly become possible to speciﬁcally transfer tumor-
eactive donor-derived  T cells as part of the trans-
lantation strategy for the treatment of a variety of
ematolymphoid and epithelial-derived malignancies.
articularly in the setting of nonmyeloablative
SCT, we predict that the scheduled delivery of do-
or-derived  T-cell DLI will be associated with
inimal to no GVHD, a lower risk of graft rejection,
nd a measurably lower risk of relapse, thus translating
nto a corresponding increase in long-term DFS and
verall survival in patients undergoing such therapy.
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